66735-24-8 Usage
Uses
Used in Pharmaceutical Industry:
4-Amino-6-chloro-2-methylquinoline is used as an active pharmaceutical ingredient for the development of medications targeting various infectious diseases. Its antimicrobial and antiprotozoal properties are particularly valuable in this context.
Used in Antimalarial Treatments:
In the field of antimalarial research, 4-Amino-6-chloro-2-methylquinoline is utilized as a potential therapeutic agent for treating malaria. Its effectiveness against the Plasmodium parasites responsible for malaria has been a subject of study.
Used in Treatment of Other Infectious Diseases:
Beyond malaria, 4-Amino-6-chloro-2-methylquinoline is also being investigated for its potential in treating other infectious diseases. Its broad-spectrum antimicrobial activity suggests it could be a versatile component in the development of new treatments.
Safety Precautions:
It is crucial to handle 4-Amino-6-chloro-2-methylquinoline with care due to its potential harmful effects if ingested, inhaled, or comes into contact with the skin or eyes. Adequate safety measures should be taken during its production, use, and disposal to minimize risks.
Check Digit Verification of cas no
The CAS Registry Mumber 66735-24-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,6,7,3 and 5 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 66735-24:
(7*6)+(6*6)+(5*7)+(4*3)+(3*5)+(2*2)+(1*4)=148
148 % 10 = 8
So 66735-24-8 is a valid CAS Registry Number.
InChI:InChI=1/C10H9ClN2/c1-6-4-9(12)8-5-7(11)2-3-10(8)13-6/h2-5H,1H3,(H2,12,13)
66735-24-8Relevant academic research and scientific papers
Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
-
Page/Page column 16, (2010/02/05)
The present invention provides phenyl urea and phenyl thiourea derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors, of formula (I) in which: Z represents oxygen or sulfur; and R1to R7represent various substituent groups; and pharmaceutically acceptable salts thereof. In particular, these compounds are of potential use in the treatment of obesity including obesity observed in Type 2(non-insulin-dependent) diabetes patients and/or sleep disorders.
